Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05069740 · ClinicalTrials.gov registry record · Early Phase 1
Endometriosis and Microvascular Dysfunction: Role of Inflammation
A Early Phase 1 study of Endometriosis, sponsored by Penn State University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05069740: Recruiting Early Phase 1 study of Endometriosis, sponsored by Penn State University.
NCT05069740 is a Early Phase 1 study of Endometriosis that is actively recruiting participants, run by Penn State University. The registered enrollment target is 24 participants, below the 264-participant average among 48 other Endometriosis trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05069740, a Early Phase 1 study of Endometriosis, is actively recruiting participants, sponsored by Penn State University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to better understand the underlying mechanisms associated with elevated cardiovascular disease risk in women with endometriosis, and to measure the effectiveness of emerging endometriosis treatments on outcomes specific to cardiovascular dysfunction. Epidemiologic data demonstrate a clear association between endometriosis, reproductive risk factors, inflammation and cardiovascular (CV) risk. Circulating factors, low-density lipoprotein (LDL) and oxidized LDL (oxLDL), are two of many biomarkers of cardiovascular and inflammatory disease of endometriosis. An important signaling mechanism through which circulating LDL and oxLDL act is the lectin-like oxidized LDL receptor (LOX-1). LOX-1 signal transduction functionally results in pronounced endothelial dysfunction, a hallmark of CV. The investigators hypothesis that one factor mediating the elevated risk of cardiovascular disease in endometriosis is systemic inflammation and activation of LOX-1 receptor mechanisms.
Primary Outcome
doppler flowmetry used to measure cutaneous vascular conductance (cvc = red cell flux/mean arterial pressure) to assess microvascular endothelial function
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Salsalate Pill
Study Locations (1)
Pennsylvania
- The Pennsylvania State University - University Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-01-01 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
What NCT05069740 shows while recruiting
NCT05069740 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 264-participant average among 48 other Endometriosis trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Endometriosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05069740 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05069740 about?
NCT05069740 is a clinical study titled "Endometriosis and Microvascular Dysfunction: Role of Inflammation". The purpose of this study is to better understand the underlying mechanisms associated with elevated cardiovascular disease risk in women with endometriosis, and to measure the effectiveness of emerging endometriosis treatments on outcomes specific to cardiovascular dysfunction. Epidemiologic data ...
What is the current status of trial NCT05069740?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2022-01-01. Estimated completion is 2026-12-31.
What conditions does trial NCT05069740 study?
This clinical trial studies the following conditions: Endometriosis.
What interventions are being tested in trial NCT05069740?
The interventions under investigation include: Placebo (DRUG), Salsalate Pill (DRUG).
Who is sponsoring clinical trial NCT05069740?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05069740 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometriosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05069740's enrollment target sits among peer trials
24 45th of 48 higher than 3 of 48 other Endometriosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometriosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cardiovascular Disease Risk in Women With Endometriosis
RECRUITING · Early Phase 1
-
Thromboxane Function in Women With Endometriosis
RECRUITING · Phase 4
-
Interdisciplinary Group Care for the Treatment of Endometriosis-associated Pain
RECRUITING · NA
-
The Impact of Yoga on Endometriosis-Related Pain
RECRUITING · NA
-
Physical Therapy After Endometriosis Excision
RECRUITING · NA
-
Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET / MRI
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI